{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-XR2W92EW/10cec092-b8ac-40b5-8aad-c127d98767ac/PDF","dcterms:extent":"666 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-XR2W92EW/321ff696-a0b6-4ff6-9ab8-a403ba5f7767/TEXT","dcterms:extent":"42 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-XR2W92EW","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2024","dc:creator":["Kolenc, Petra","Krošelj, Marko","Novak, Doroteja"],"dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"letnik:75"},{"@xml:lang":"sl","#text":"str. 83-93"}],"dc:identifier":["ISSN:0014-8229","COBISSID_HOST:196302339","URN:URN:NBN:SI:doc-XR2W92EW"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"ciljano radionuklidno zdravljenje"},{"@xml:lang":"en","#text":"nuclear medicine"},{"@xml:lang":"sl","#text":"Nuklearna medicina"},{"@xml:lang":"en","#text":"radioactivity"},{"@xml:lang":"sl","#text":"radioaktivnost"},{"@xml:lang":"sl","#text":"Radiofarmacija"},{"@xml:lang":"sl","#text":"radiofarmaki"},{"@xml:lang":"en","#text":"radiopharmaceuticals"},{"@xml:lang":"en","#text":"targeted radionuclide therapy"},{"@xml:lang":"sl","#text":"teranostika"},{"@xml:lang":"en","#text":"theranostic"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Radiofarmaki v teranostiki| Theranostic radiopharmaceuticals|"},"dc:description":[{"@xml:lang":"sl","#text":"Radiopharmaceuticals are radioactive drugs that, based on their intended use or type of radiation, are categorized into radiodiagnostics, used in disease identification, and radiotherapeutics, employed in the treatment process. The term “theranostics” stems from the combination of the words “therapy” and “diagnostics.” In the field of nuclear medicine, the concept of theranostics is implemented by integrating molecular imaging technique and targeted radionuclide therapy. In the present work, we describe examples of overexpression of molecular targets on tumour cells and radiopharmaceuticals that selectively target them. We present established theranostic pairs of radiopharmaceuticals used in the treatment of patients with tumours expressing somatostatin receptors or prostate-specific membrane antigen on cell surfaces. In the following we present a translational study employing potential radiopharmaceuticals that selectively target the cholecystokinin-2/gastrin receptor. In the final part, we will shift from molecular targets overexpressed on cell surface to the target expressed in the tumour microenvironment, namely fibroblast-activating protein"},{"@xml:lang":"sl","#text":"Radiofarmaki so radioaktivna zdravila, ki jih glede na namen uporabe oz. tip sevanja delimo na radiodiagnostike, ki jih uporabljamo pri opredeljevanju bolezni, in radioterapevtike, za uporabo v procesu zdravljenja. Izraz teranostika izhaja iz združitve besed »terapija« in »diagnostika«. Na področju nuklearne medicine koncept teranostike implementiramo s povezovanjem slikovne diagnostike in ciljanega radionuklidnega zdravljenja. V prispevku se bomo seznanili s primeri povečane izraženosti molekularnih tarč na tumorskih celicah in radiofarmaki, ki se selektivno vežejo nanje. Kot primere predstavljamo uveljavljene teranostične pare radiofarmakov, ki jih uporabljamo pri obravnavi bolnikov z raki, ki imajo na površini celic izražene somatostatinske receptorje ali prostatični specifični membranski antigen. Pogledali si bomo primer translacijske raziskave razvoja potencialnih radiofarmakov, ki se selektivno vežejo na holecistokinin-2/gastrinski receptor. V zadnjem delu se bomo seznanili še s primerom z aktualnega področja, kjer je tarča za eventualno vezavo radiofarmaka, prisotna v tumorskem mikrookolju in ne na sami rakavi celici, tj. fibroblaste aktivirajoči protein"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-XR2W92EW","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-XR2W92EW"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-XR2W92EW/10cec092-b8ac-40b5-8aad-c127d98767ac/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-XR2W92EW/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-XR2W92EW"}}}}